CA3246681A1 - Dérivés d’amine de pyrido-[3,4-d]pyridazine utiles en tant que dérivés de nlrp3 - Google Patents

Dérivés d’amine de pyrido-[3,4-d]pyridazine utiles en tant que dérivés de nlrp3

Info

Publication number
CA3246681A1
CA3246681A1 CA3246681A CA3246681A CA3246681A1 CA 3246681 A1 CA3246681 A1 CA 3246681A1 CA 3246681 A CA3246681 A CA 3246681A CA 3246681 A CA3246681 A CA 3246681A CA 3246681 A1 CA3246681 A1 CA 3246681A1
Authority
CA
Canada
Prior art keywords
compound
pyrido
amino
pyridazin
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3246681A
Other languages
English (en)
Inventor
Stéphane DORICH
Amandine Chefson
Stéphane Ciblat
Original Assignee
Ventus Therapeutics US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/704,983 external-priority patent/US11618751B1/en
Application filed by Ventus Therapeutics US Inc filed Critical Ventus Therapeutics US Inc
Publication of CA3246681A1 publication Critical patent/CA3246681A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"La présente divulgation concerne des inhibiteurs de NLRP3 de formule (I), ou un sel pharmaceutiquement acceptable, un solvate, un clathrate, un hydrate, un stéréoisomère, un tautomère, un composé marqué isotopiquement ou un promédicament de ceux-ci, le cycle A étant un hétérocycloalkyle monocyclique de 5 à 8 chaînons comprenant au moins un atome de cycle O, p étant 0 ou 1, et R1, R2, R3, R4 et X étant tels que définis dans la description, utiles dans le traitement de maladies et de troubles inhibés par ladite protéine."
CA3246681A 2022-03-25 2023-03-24 Dérivés d’amine de pyrido-[3,4-d]pyridazine utiles en tant que dérivés de nlrp3 Pending CA3246681A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17/704,983 US11618751B1 (en) 2022-03-25 2022-03-25 Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US17/704,983 2022-03-25
US202263420930P 2022-10-31 2022-10-31
US63/420,930 2022-10-31
US202363443874P 2023-02-07 2023-02-07
US63/443,874 2023-02-07
PCT/US2023/064967 WO2023183943A1 (fr) 2022-03-25 2023-03-24 Dérivés de pyrido-[3,4-d]pyridazine-amine utiles en tant que dérivés de nlrp3

Publications (1)

Publication Number Publication Date
CA3246681A1 true CA3246681A1 (fr) 2023-09-28

Family

ID=86329581

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3246681A Pending CA3246681A1 (fr) 2022-03-25 2023-03-24 Dérivés d’amine de pyrido-[3,4-d]pyridazine utiles en tant que dérivés de nlrp3

Country Status (13)

Country Link
EP (1) EP4499638A1 (fr)
JP (1) JP2025510414A (fr)
KR (1) KR20250005125A (fr)
CN (1) CN119137121A (fr)
AU (1) AU2023238121A1 (fr)
CA (1) CA3246681A1 (fr)
CL (1) CL2024002855A1 (fr)
CO (1) CO2024013702A2 (fr)
IL (1) IL315842A (fr)
MX (1) MX2024011697A (fr)
PE (1) PE20250605A1 (fr)
TW (1) TW202345836A (fr)
WO (1) WO2023183943A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
TW202313577A (zh) 2021-06-04 2023-04-01 瑞士商赫孚孟拉羅股份公司 新穎化合物
US12331048B2 (en) * 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
KR20250106322A (ko) * 2022-12-28 2025-07-09 장춘 진사이언스 파마슈티컬 씨오., 엘티디. 피리다진계 nlrp3 억제제 화합물, 약학 조성물 및 이의 제조 방법과 용도
WO2025059481A1 (fr) 2023-09-13 2025-03-20 Ventus Therapeutics U.S., Inc. Formes solides d'un inhibiteur de nlrp3 et leurs utilisations
WO2025153532A1 (fr) 2024-01-16 2025-07-24 NodThera Limited Polythérapies faisant intervenir des inhibiteurs de nlrp3 et des agonistes de glp-1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US11618751B1 (en) * 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CR20240093A (es) * 2021-08-25 2024-05-23 Ptc Therapeutics Inc Inhibidores de NLRP3

Also Published As

Publication number Publication date
MX2024011697A (es) 2024-11-08
JP2025510414A (ja) 2025-04-14
IL315842A (en) 2024-11-01
PE20250605A1 (es) 2025-02-26
CN119137121A (zh) 2024-12-13
WO2023183943A1 (fr) 2023-09-28
KR20250005125A (ko) 2025-01-09
TW202345836A (zh) 2023-12-01
CO2024013702A2 (es) 2024-11-08
CL2024002855A1 (es) 2025-02-14
AU2023238121A1 (en) 2024-10-10
EP4499638A1 (fr) 2025-02-05

Similar Documents

Publication Publication Date Title
AU2023263450B2 (en) Pyridazine compounds for inhibiting nlrp3
CA3246681A1 (fr) Dérivés d’amine de pyrido-[3,4-d]pyridazine utiles en tant que dérivés de nlrp3
CA2971024C (fr) Composes d'heteroaryle a cycle condense et leur utilisation a titre d'inhibiteurs de trk
US12398136B2 (en) Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
EP4037677B1 (fr) Antagonistes du récepteur m4 d'acétylcholine muscarinique
WO2014146494A1 (fr) Composé β-aminocarbonyle, procédé de préparation, composition pharmaceutique et utilisation correspondants
TWI860797B (zh) 新穎acc抑制劑
CN105153154A (zh) Btk抑制剂及其用途
JP7748560B2 (ja) ピラゾロ縮合環化合物及びその使用
JP2010513383A (ja) セロトニン、ドーパミンおよびノルエピネフリン再取り込み阻害剤としてのアザビサイクリック化合物
EA051595B1 (ru) Соединения пиридазина для ингибирования nlrp3
CN119490507A (zh) 一种新型激酶抑制剂
WO2022117012A1 (fr) Inhibiteur de jak spirocyclique, composition pharmaceutique le contenant, et son application

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240924

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241008

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241008

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241106

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250307

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250307

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250307

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260309

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260309

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260416

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260416

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260416

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260417

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260420

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260420

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260423

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260423

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260423